GLENMARK PHARMACEUTICALS LTD. - 532296 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- HARISH KUBERDesignation :- Company Secretary and Compliance Officer GLENMARK PHARMACEUTICALS LTD. - 532296 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2020.
Enclosed please find herewith the Compliance Certificate under Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Half Year ended 31st March, 2020. GLENMARK PHARMACEUTICALS LTD. - 532296 - Certificate From Practicing Company Secretary Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2020.
Enclosed please find herewith the copy of the certificate issued by M/s. Savita Jyoti Associates, Company Secretaries under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Half Year ended 31st March, 2020. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark divests VWash, a female intimate hygiene wash, to Hindustan Unilever Glenmark gets tentative nod from USFDA for generic type-2 diabetes tablets
The product is a generic version of AstraZeneca AB's Farxiga tablets GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin Tablets, 5 mg and 10 mg More drug licensing deals will play a big part in paring Glenmark's debt
The company's US sales growth has remained subdued due to intense competition for its dermatology range.
Glenmark inks licensing pact with Hikma for commercialisation of nasal spray Ryaltris in US
The licensing pact for Ryaltris has been signed between the company's Swiss subsidiary, Glenmark Specialty SA and Hikma Pharmaceuticals PLC (Hikma). Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals and Hikma enter into an Exclusive Licensing Agreement for commercializing Ryaltris(tm) Seasonal Allergic Rhinitis Nasal Spray in the US
Glenmark's lack of growth levers in Q3 may keep its stock subdued
Some recent launches in the US have seen a significant price erosion, which led to the drop in revenue.Operating performance took a hit due to lower economies of scale